100 results
S-3ASR
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
with GLP-1 therapeutics to manage their type 2 diabetes.
Our Strategy
Our goal is to become a leading biotechnology company focused on developing … components of our strategy are to:
Advance EFX through clinical development in both pre-cirrhotic (F2-F3) and cirrhotic (F4, compensated) MASH. We believe
8-K
EX-99.1
AKRO
Akero Therapeutics Inc
10 May 24
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:17am
clinical trials; Akero’s ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results
PRE 14A
AKRO
Akero Therapeutics Inc
16 Apr 24
Preliminary proxy
4:30pm
Vice President, Commercial Strategy
William White, J.D.
Mr. White has served as our Executive Vice President, Chief Financial Officer and Head … served as our Senior Vice President of Commercial Strategy since January 2023. Before joining the Company, Mr. Lamy provided commercial strategy
8-K
EX-99.1
ugqln2ebm948nsvnm
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
l4ggn6oubt1
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.1
77kierun 4xi
29 Feb 24
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
EX-99.1
oq9p c0nsvr83o
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
w3o 5x97v2gscu73ty
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
EX-99.1
2uv0q51p8jpht2dit
13 Nov 23
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:15am
8-K
EX-99.1
3q5m0
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
5x0o9cg16959aitnpp
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.2
92w1ds 2od5mfsx4n
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
10kjed0
11 Aug 23
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
6:09am
8-K
EX-99.1
oyckvjiu7 ia
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
crmjjj8
5 Jun 23
Results of Operations and Financial Condition
8:05am